Checkpoint Therapeutics, Inc. (NASDAQ:CKPT – Get Rating) CEO James F. Oliviero III sold 5,483 shares of the firm’s stock in a transaction that occurred on Thursday, March 2nd. The shares were sold at an average price of $5.00, for a total value of $27,415.00. Following the completion of the transaction, the chief executive officer now owns 144,090 shares of the company’s stock, valued at $720,450. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Checkpoint Therapeutics Stock Performance
Shares of CKPT stock opened at $5.20 on Monday. The firm’s 50-day moving average is $5.43 and its 200-day moving average is $2.86. The stock has a market cap of $48.36 million, a price-to-earnings ratio of -0.60 and a beta of 1.52. Checkpoint Therapeutics, Inc. has a 52-week low of $3.56 and a 52-week high of $19.50.
Analysts Set New Price Targets
Several equities analysts recently weighed in on CKPT shares. Lake Street Capital decreased their target price on shares of Checkpoint Therapeutics from $41.00 to $32.00 in a research note on Thursday. HC Wainwright restated a “buy” rating and set a $76.00 price objective on shares of Checkpoint Therapeutics in a research note on Thursday. Finally, B. Riley upped their target price on shares of Checkpoint Therapeutics from $7.00 to $15.00 and gave the company a “buy” rating in a report on Monday, December 19th.
Institutional Investors Weigh In On Checkpoint Therapeutics
About Checkpoint Therapeutics
Checkpoint Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Its product portfolio includes CK-301, CK-101, CK-103, CK-302, and Anti-CAIX. The company was founded on November 10, 2014 and is headquartered in Waltham, MA.
- Get a free copy of the StockNews.com research report on Checkpoint Therapeutics (CKPT)
- MarketBeat Week in Review – 2/27 – 3/3
- The 3 Most Upgraded Stocks Are Reversing
- How to Find Blue Chip Dividend Stocks
- Zscaler, Inc Plummets, Is It Time To Buy The Dip?
- What is a Good Dividend Yield? How to Decide
Receive News & Ratings for Checkpoint Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkpoint Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.